Zoetis Announces New 15-Month Duration of Immunity Claim for Vanguard® crLyme Vaccine for Dogs

PARSIPPANY, N.J. — Aug. 10, 2017 — Zoetis today announced that the United States Department of Agriculture (USDA) has granted approval for a 15-month duration of immunity (DOI) claim for Vanguard® crLyme — the longest DOI claim of any canine Lyme disease vaccine on the market.  Vanguard crLyme vaccine, introduced to the market in January 2016, is the first and only multivalent recombinant Lyme vaccine to aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi, the causative agent of Lyme disease in dogs.

“Offering our customers the longest duration of immunity claim with Vanguard crLyme is yet another example of Zoetis leading with science that addresses the needs of veterinarians and the animals in their care,” said J. Michael McFarland, DVM, DAVBP, Executive Director, Companion Animal Marketing at Zoetis. “With the combination of this 15-month claim and the innovative coverage that Vanguard crLyme provides to help protect dogs from Borrelia burgdorferi infection, veterinarians can feel confident when using it that they are helping to provide year-round Lyme disease protection for their canine patients.”

“One of the most important aspects of efficacy of an annual vaccine is that it truly lasts the full 12 months or more. In the past, breaks have been associated with Ixodes tick exposure as circulating OspA titers have waned prior to the end of the year with other Lyme vaccines currently on the market,” said Richard E. Goldstein*, DVM, DACVIM, DECVIM-CA, Chief Medical Officer at the Animal Medical Center in New York City.  “Now that Vanguard crLyme has a proven 15-month duration of immunity, that is no longer a concern. Veterinarians and pet owners can be confident that Vanguard crLyme vaccination will provide excellent protection to help prevent Lyme disease in their dogs and that protection is in place for more than a year.” 

About Vanguard crLyme
Vanguard crLyme is a next-generation multivalent vaccine which contains outer surface protein A (OspA) protein and a single OspC protein that is composed of antigenic material from seven common types of OspC found in Lyme-infected dogs in the U.S.1 Its uniquely targeted design helps provide a broad spectrum of coverage while delivering a low-reactive vaccine by minimizing the amount of extraneous proteins administered to the dog.

Scientific research has demonstrated that there are multiple variants of OspC that have been associated with Lyme-infected dogs.1 All other commercially available vaccines contain at most only one type of OspC.

Vanguard crLyme is now supported by our Companion Animal Immunization Support Guarantee for 15 months.

About Lyme Disease
Lyme disease is a bacterial infection transmitted via the Ixodes spp. ticks, commonly known as the blacklegged tick.  In the eastern United States it is also frequently referred to as the deer tick.  It is one of the most common tick-borne illnesses transmitted to dogs. The Companion Animal Parasite Council reported 170,240 cases thus far in 2017 — meaning one in 16 dogs in the United States tests positive for the disease.2

Clinical signs of Lyme disease in dogs include lameness, enlarged lymph nodes, fever, lack of appetite and depression. In some cases, it can also lead to kidney failure. It is possible for a dog to be subclinically infected with the disease without showing any clinical signs.

To learn more about Vanguard crLyme, visit www.vanguardcrlyme.com.

About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.

*Dr. Richard Goldstein is a consultant to Zoetis.

For Further information contact:
Colleen White       

Lindsey Goodman
Archer Malmo

1 Rhodes DV, Earnhart CG, Mather TN, Meeus PF, Marconi RT. Identification of Borrelia burgdorferi OspC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design. Vet J. 2013;198(2):412-418.
2 Parasite prevalence maps. Companion Animal Parasite Council.  
https://www.capcvet.org/ Accessed August 10, 2017.



Mon–Fri, 8:30am–6:30pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.